Search - tctmd.com

Displaying 61 - 74 of 74

Sort: Relevancy | Date

News Daily News

Las Noticias Negativas sobre las Estatinas se asociaron a su Interrupción y a Más Riesgo CV

Michael O'Riordan

December 02, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

L.A. McKeown

July 29, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

News Daily News

El Controvertido Ezetimibe Ayuda cuando se Incorpora al Tratamiento con Estatinas

Yael L. Maxwell

June 05, 2015

News Daily News

La Alta Reactividad a la Aspirina Justo Antes de la PCI se asocia a Peores Resultados

September 02, 2014

News Daily News

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

May 27, 2011

Advertisement

Las Noticias Negativas sobre las Estatinas se asociaron a su Interrupción y a Más Riesgo CV

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

FDA approves Repatha to treat certain patients with high cholesterol

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

La Evidencia de la Regresión de la Placa Avala el Uso Combinado de Ezetimibe+Estatinas

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

El Controvertido Ezetimibe Ayuda cuando se Incorpora al Tratamiento con Estatinas

La Alta Reactividad a la Aspirina Justo Antes de la PCI se asocia a Peores Resultados

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content